Where is the live CopyMark page for USPTO serial 86091302?

The live record is at https://getcopymark.com/trademark/86091302. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns TREATING THE COMORBIDITIES OF SICKLE CELL DISEASE?

According to the public USPTO record for serial number 86091302, the listed owner(s) include: Prolong Pharmaceuticals, LLC.

What is the current status of TREATING THE COMORBIDITIES OF SICKLE CELL DISEASE?

TREATING THE COMORBIDITIES OF SICKLE CELL DISEASE (86091302) currently shows USPTO status code 603 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Which trademark classes cover TREATING THE COMORBIDITIES OF SICKLE CELL DISEASE?

The public record lists International Classes: 040. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: TREATING THE COMORBIDITIES OF SICKLE CELL DISEASE Serial# 86091302 | status 603; last event MAB3 | Trademark Info & Attorney Guidance

Q: What is USPTO serial number 86091302?

Serial number 86091302 is the USPTO application identifier for the mark TREATING THE COMORBIDITIES OF SICKLE CELL DISEASE. It is used to track examination, publication, and registration of this trademark.

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with TREATING THE COMORBIDITIES OF SICKLE CELL DISEASE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

Prolong Pharmaceuticals, LLC
Plainfield, NJ
Other trademarks owned by Prolong Pharmaceuticals, LLC

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Erik M. Pelton

ERIK M PELTON ERIK M PELTON & ASSOCIATES PLLCPO BOX 100637ARLINGTON, VA 22210-3637UNITED STATES

Goods and services

Class	Description	Status	First use
040	Custom manufacturing services for others in the field of pharmaceuticals; manufacturing services in the field of pharmaceuticals to the order and specification of others; contract manufacturing services in the field of pharmaceuticals	ACTIVE	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Sep 22, 2015	MAB3	ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL	—
Sep 21, 2015	ABN3	ABANDONMENT - AFTER EX PARTE APPEAL	—
Sep 21, 2015	EXPT	EXPARTE APPEAL TERMINATED	—
Jun 5, 2015	EXPA	EX PARTE APPEAL-REFUSAL AFFIRMED	—
Apr 21, 2015	RBFT	REPLY BRIEF FILED - CHECK TTAB FILES	—
Apr 9, 2015	GNSN	NOTIFICATION OF EXAMINERS STATEMENT E-MAILED	—
Apr 9, 2015	GNES	EXAMINERS STATEMENT E-MAILED	—
Apr 9, 2015	CNES	EXAMINERS STATEMENT - COMPLETED	—
Feb 13, 2015	JURT	JURISDICTION RESTORED TO EXAMINING ATTORNEY	—
Dec 9, 2014	EXPI	EX PARTE APPEAL-INSTITUTED	—
Dec 9, 2014	EXAF	EXPARTE APPEAL RECEIVED AT TTAB	—
Jun 9, 2014	GNFN	NOTIFICATION OF FINAL REFUSAL EMAILED	—
Jun 9, 2014	GNFR	FINAL REFUSAL E-MAILED	A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 9, 2014	CNFR	FINAL REFUSAL WRITTEN	A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 7, 2014	TEME	TEAS/EMAIL CORRESPONDENCE ENTERED	—
May 6, 2014	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
May 6, 2014	TROA	TEAS RESPONSE TO OFFICE ACTION RECEIVED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 30, 2014	GNRN	NOTIFICATION OF NON-FINAL ACTION E-MAILED	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 30, 2014	GNRT	NON-FINAL ACTION E-MAILED	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 30, 2014	CNRT	NON-FINAL ACTION WRITTEN	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 30, 2014	DOCK	ASSIGNED TO EXAMINER	—
Oct 22, 2013	NWOS	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	—
Oct 18, 2013	NWAP	NEW APPLICATION ENTERED	—

TREATING THE COMORBIDITIES OF SICKLE CELL DISEASE